

Amendment to the Claims

Please amend claims 13 and 14 as follows:

1. (original) A composition comprising:

an isolated nucleic acid molecule that encodes an immunogen; and

an isolated nucleic acid molecule that encodes one or more proteins of selected from the group consisting of: Fos, c-jun, Sp-1, Ap-1, Ap-2, p38, p65Rel, MyD88, IRAK, TRAF6, Ikb, Inactive NIK, SAP K, SAP-1, JNK, interferon response genes, NFkB, Bax, TRAIL, TRAILrec, TRAILrecDRC5, TRAIL-R3, TRAIL-R4, RANK, RANK LIGAND, Ox40, Ox40 LIGAND, NKG2D, MICA, MICB, NKG2A, NKG2B, NKG2C, NKG2E, NKG2F, TAP1, TAP2 and functional fragments thereof.
2. (original) The composition of claim 1 wherein said nucleic acid molecules are plasmids.
3. (original) The composition of claim 1 wherein said immunogen is a pathogen antigen, a cancer-associated antigen or an antigen linked to cells associated with autoimmune diseases.
4. (original) The composition of claim 3 wherein said immunogen is a pathogen antigen.
5. (original) The composition of claim 4 wherein said immunogen is a herpes simplex antigen.
6. (original) The composition of claim 5 wherein said herpes simplex antigen is HSV2gD.
7. (original) A composition comprising an isolated nucleic acid molecule comprising a nucleotide sequence that encodes an immunogen; and a nucleotide sequence that encodes one or more proteins of selected from the group consisting of: Fos, c-jun, Sp-1, Ap-1, Ap-2, p38,

p65Rel, MyD88, IRAK, TRAF6, IκB, Inactive NIK, SAP K, SAP-1, JNK, interferon response genes, NFκB, Bax, TRAIL, TRAILrec, TRAILrecDRC5, TRAIL-R3, TRAIL-R4, RANK, RANK LIGAND, O_x40, O_x40 LIGAND, NKG2D, MICA, MICB, NKG2A, NKG2B, NKG2C, NKG2E, NKG2F, TAP1, TAP2 and functional fragments thereof.

8. (original) The composition of claim 7 wherein said nucleic acid molecule is a plasmid.

9. (original) The composition of claim 7 wherein said immunogen is a pathogen antigen, a cancer-associated antigen or an antigen linked to cells associated with autoimmune diseases.

10. (original) The composition of claim 9 wherein said immunogen is a pathogen antigen.

11. (original) The composition of claim 10 wherein said immunogen is a herpes simplex antigen.

12. (original) The composition of claim 11 wherein said herpes simplex antigen is HSV2gD.

13. (currently amended) An injectable pharmaceutical composition comprising the composition of claims ~~1-12~~ 1.

14. (currently amended) A method of inducing an immune response in an individual against an immunogen comprising administering to said individual a composition of claims ~~1-12~~ 1.

15. (original) A recombinant vaccine comprising a nucleotide sequence that encodes an immunogen operably linked to regulatory elements, a nucleotide sequence that encodes one or more proteins of selected from the group consisting of: Fos, c-jun, Sp-1, Ap-1, Ap-2, p38, p65Rel, MyD88, IRAK, TRAF6, IκB, Inactive NIK, SAP K, SAP-1, JNK, interferon response genes, NFκB, Bax, TRAIL, TRAILrec, TRAILrecDRC5, TRAIL-R3, TRAIL-R4,

RANK, RANK LIGAND, Ox40, Ox40 LIGAND, NKG2D, MICA, MICB, NKG2A, NKG2B, NKG2C, NKG2E, NKG2F, TAP1, TAP2 and functional fragments thereof.

16. The recombinant vaccine of claim 15 wherein said immunogen is a pathogen antigen, a cancer-associated antigen or an antigen linked to cells associated with autoimmune diseases.

17. (original) The recombinant vaccine of claim 16 wherein said immunogen is a pathogen antigen.

18. (original) The recombinant vaccine of claim 17 wherein said recombinant vaccine is a recombinant vaccinia vaccine.

19. (original) A method of inducing an immune response in an individual against an immunogen comprising administering to said individual a recombinant vaccine of claim 17.

20. (original) A live attenuated pathogen comprising a nucleotide sequence that encodes one or more proteins of selected from the group consisting of: Fos, c-jun, Sp-1, Ap-1, Ap-2, p38, p65Rel, MyD88, IRAK, TRAF6, Ikb, Inactive NIK, SAP K, SAP-1, JNK, interferon response genes, NFkB, Bax, TRAIL, TRAILrec, TRAILrecDRC5, TRAIL-R3, TRAIL-R4, RANK, RANK LIGAND, Ox40, Ox40 LIGAND, NKG2D, MICA, MICB, NKG2A, NKG2B, NKG2C, NKG2E, NKG2F, TAP1, TAP2 and functional fragments thereof.

21. (original) A method of immunizing an individual against a pathogen comprising administering to said individual the live attenuated pathogen of claim 20.